Researchers from MDS Pharma Services detail new studies and findings in the area of attention deficit hyperactivity disorder therapy

Researchers detail in 'Phase I, double-blind, randomized, placebo-controlled, dose-escalation study of the effects on blood pressure of abrupt cessation versus taper down of guanfacine extended-release tablets in adults aged 19 to 24 years,' new data in attention deficit hyperactivity disorder. "Guanfacine hydrochloride is an alpha(2a)-adrenoreceptor agonist found to be effective in the treatment of attention-deficit/hyperactivity disorder (ADHD). Because the available immediate-release formulation requires multiple daily dosing and has been associated with rebound hypertension on abrupt cessation, an extended-release (ER) formulation has been developed for study of efficacy and...

Want to see the full article?

• Purchase this article for only $3.00